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The primary objectives of this interdisciplinary study were the synthesis of novel 
heterocyclic arylidenes and the investigation of their anticancer activity against U87 
glioblastoma cell viability. Recently, novel hybrid derivatives have been considered as potential 
candidates for treating glioblastoma, demonstrating a synergistic anticancer effect in previous 
studies. 12 heterocyclic arylidenes with various functional groups, including halogens and 
boronic acid, were produced via a Knoevenagel condensation.  These compounds and their 
starting reagents were then administered to U87 glioblastoma cancer cells at graded 
concentrations within a 12-well cell viability assay to determine each compound’s lethal 
concentration 50 (LC50). The LC50 of each compound was then compared to determine the effects 
of substituent type and position on anticancer activity.  Although these arylidenes displayed 
some anticancer effects, their high LC50 suggest they have no significant effect on U87 



































Glioblastoma multiforme (abbreviated to GBM) is a malignant astrocytoma that derives 
from astrocytes, a type of glial cell that normally nourishes the nervous tissue and maintains the 
blood-brain barrier.  GBM exhibits a high degree of invasiveness and an unprecedented 
proliferation rate, capable of infiltrating cranial nerve pathways and metastasizing throughout the 
brain’s cerebrospinal fluid.  Patients suffering from GBM present headaches, impaired balance 
and muscle coordination, temporary loss of consciousness, seizures, and visual problems.  
However, due to the lack of specific clinical symptoms, GBM can be easily misdiagnosed as an 
infection, inflammatory reaction, or an immunological disease; identifying GBM is further 
complicated if the patient already has a medical history of neurological disorders (Lee, 2016).  
Coupled with the limited regenerative capabilities of the central nervous system, patients that do 
undergo treatment do not experience a complete recovery, with most surviving only a median of 
one year and only 5% of patients surviving up to five (Haar, 2012; Eramo et al, 2006).  Although 
treatment of glioblastoma has resulted in little success, the current standard procedure for 
treating glioblastoma involves surgical removal of the tumor followed by radiotherapy and 
chemotherapy with the anticancer, alkylating agent temozolomide (Davis, 2016; Fan et al, 2013).   
Temozolomide acts as an alkylating agent that adds a methyl substituent group onto a 
guanine nucleotide, converting it into 6-O-methylguanine.  Guanine is one of the four constituent 
bases in our DNA, encoding genetic information that is essential to cell survival and 
proliferation.  The addition of a foreign chemical group onto guanine alters its structural and 
chemical characteristics, rendering the nucleotide unrecognizable to enzymes essential in DNA 
repair and replication ((Fan et al, 2013; Davis, 2016).  Furthermore, increased concentration of 
O-6-methylguanine and the decreased concentration of normal guanine also lowers the encounter 
rate between these crucial enzymes and guanine.  As a result, breakages in the DNA sequence 
accumulate, leading to missing segments of genetic information; these genetic inconsistencies 
encode dysfunctional or nonfunctional proteins that impair cancer cell survival (Fan et al, 2013). 
One particular reason though that the standard treatment for glioblastoma is rather 
ineffective is due to glioblastoma’s resistance to temozolomide (Haar, 2012; Davis, 2016).  More 
specifically, the overexpression of a gene sequence known as MGMT is shown to confer a higher 
degree of resistance against this anticancer agent, rendering the only drug for treating 
glioblastoma less effective (Carbrini et al, 2015).  The MGMT gene encodes for O6-
methylguanine DNA methyltransferase (abbreviated to MGMT), an enzyme that counteracts 
temozolomide’s cytotoxic effects by initiating mismatch DNA repair (The Cancer Genome Atlas 
Research Network, 2008; Fan et al, 2013).  MGMT facilitates DNA repair by converting 6-O-
methylguanine, the alkylated nucleotide, into normal guanine.  The activity essentially reverses 
temozolomide’s DNA damaging effects, preventing cancer cell death and conferring 
glioblastoma with a resistance against it (Haar, 2012; Davis, 2016).   
Recently, novel hybrid derivatives have been considered as potential candidates for 
treating glioblastoma, demonstrating an obstructive effect on the biochemical pathways 
necessary for cancer cell survival (Libby et al, 2018, de Moura Sperotto et al, 2019).  The main 
premise of these studies is to chemically combine two or more compounds with known 
anticancer effects and observe their activity on harvested glioblastoma cells in vitro.  The 
primary goal of these experiments is to provide an alternative set of anticancer agents that can 
effectively counteract the aggressive proliferative nature of glioblastoma and other cancers 
(Cabrini et al, 2015).  Therefore, the premise of my study investigates a primary question: are 
heterocyclic arylidenes, a type of novel hybrid derivative, effective anticancer agents against the 
proliferation of human glioblastoma brain cancer cells? 
As part of a larger collaborative research effort, I synthesized 12 heterocyclic arylidenes 
from rhodanine-3-acetic acid and a set of benzaldehydes with various substituent groups in an 
enzyme-catalyzed controlled reflux.  I then investigated the effects of these hybrid derivatives 
and their reagents in 12-well cell viability assays to determine each compound’s lethal 










































12 heterocyclic arylidenes from rhodanine-3-acetic acid and a set of benzaldehydes via a 
3-hour, pancreatin-catalyzed Knoevenagel condensation (Fig. 1).  This condensation reaction 
essentially marries rhodanine-3-acetic acid and a benzaldehyde with a carbon-carbon double 





Fig. 1 Chemical equation of the Knoevenagel condensation of heterocyclic arylidenes 
 
Before producing all 12 novel heterocyclic arylidenes, a series of experiments were 
conducted to determine the efficacy of different catalysts in the syntheses of these compounds.  8 
enzymes were tested in a series of controlled refluxes, in which .176 g of 4-chlorobenzaldehyde 
and .239 g of rhodanine-3-acetic acid were refluxed in a water-dimethyl sulfoxide solution for 3 
hours at 50-55°C.  .2 g of the selected enzyme was also added to each controlled reflux reaction 
to determine their efficacy as a biocatalyst.  Out of all 8 catalysts investigated, pancreatin had the 
highest and purest yield, producing 86% with no residual starting reagent.   
After selecting the optimal catalyst, .239 g of rhodanine-3-acetic acid, .2 g of pancreatin, 
and .00125 mol of a selected benzaldehyde were refluxed using the same experimental set-up.  
These benzaldehydes varied depending on the type of substituent group and its placement on the 
compound’s benzene ring.  Benzaldehydes used during this study contained fluorine, chlorine, 
bromine, or boronic acids, with each substituent group placed on the 2nd, 3rd, or 4th position on 
the benzene ring.  In total, 12 benzaldehydes with various substituent groups and positions were 
used.  Although the benzaldehydes of interest were consistently .00125 moles, the amount of 
each compound varied depending on its molecular weight and physical state.   
After adding each reagent into a 25-ml round-bottom flask and attaching a water-cooled 
condenser to the flask, the apparatus was placed on a magnetic hot plate set to 50-55°C and 
refluxed for 3 hours.  Once the reflux reached completion, 30 mL of saturated NaCl solution 
were poured into the mixture to precipitate more product out of solution.  The reaction mixture 
was then vacuum-filtered with 500 mL boiling deionized water to purify the solid product.  After 
a 30 to 60-minute drying period, the product was transferred into a labelled vial and placed in a 
high vacuum system overnight to ensure complete desiccation.   
After thoroughly drying to remove any residual water, final product was weighed to 
calculate its percent yield.  A small sample of that product and their starting reagents were taken 
to conduct infrared (IR) and nuclear magnetic resonance (NMR) analyses.  These IR and NMR 
readings of the final product to those of its reagents to determine the presence and purity of the 























All 12 heterocyclic arylidenes and a majority of their starting reagents were tested on 
U87 human glioblastoma cancer cells using a 12-well cell viability assay, in which each assay 
tested one hybrid compound.  This procedure covered three days and was conducted in triplicates 
to measure, compare, and verify data.  Along with testing these heterocyclic arylidenes, their 
reagents were also tested.  Over the course of several months, I had made 54 plates.   
On the first day, glioblastoma cells were stained to determine the volume of cell culture 
needed to grow 10,000 cells in each well.  90 µL trypan blue dye were added into a 1.5 µL 
microcentrifuge tube, setting it aside for a later step.  2 mL of trypsin were then added to a 
glioblastoma cell plate in order to detach the cancer cells adhering to the plate’s surface.  
Afterwards, 10 µL of the trypsinized cell suspension were pipetted into the 90 µL trypan blue 
dye and mixed thoroughly.  The purpose of staining the glioblastoma cancer cells with trypan 
blue is to record the number of live cells after transferring 10 µL of the stained cell culture onto a 
hemocytometer grid.  The number of cancer cells present was then calculated to determine the 
volume needed to culture 10,000 cells in each well on the 12-well plate.  After adding the 
calculated volume with 13 mL media, 1,000 µL of the cell suspension mixture were pipetted into 
each well and incubated overnight at 37°C with 5% CO2 to allow the glioblastoma cells to 
adhere to the wells. 
On the second day, I made my dilutions for each well in my 12-well cell viability assay.  
20 mg of my compound of interest was weighted and transferred it into a 1.5-mL 
microcentrifuge tube.  Afterwards, 1 mL of dimethyl sulfoxide was added in order to dissolve the 
compound and make a primary stock solution.  After organizing a set of 11 2-mL 
microcentrifuge tubes on a grid, 1,000 µL of media were pipetted into all 11 microcentrifuge 
tubes; 800 µL of media were added to the first tube.  200 µL of my primary stock solution were 
pipetted and diluted into 1,800 µL of media solution to produce a 2 mg/mL concentration.  The 
mixture was then mixed and 1,000 µL of the first dilution was pipetted and added it to the next 
microcentrifuge tube in order to make a dilution that was half the concentration of my first.  All 
subsequent concentrations on the plate were half of the previous concentration until all 11 
microcentrifuge tubes are filled.  On the 11th tube, an excess 1,000 µL of the dilution was 
discarded so that each 2-mL microcentrifuge tube contained 1,000 µL of diluted compound.  
Along with these dilutions, there was a control that only contained 1,000 µL media.  1,000 µL of 
each dilution was administered to their corresponding wells on the 12-well plate and added 1,000 
µL of media to the reserved control well.  Once all the dilutions have been added to the 12-well 
plate, the glioblastoma cancer cells were again incubated in an enclosed chamber at 37°C with 
5% CO2 for another 24 hours. 
On the third day, the media was removed and 1 mL methanol was added into each 
emptied well.  These plates were allowed to rest for 5 minutes to the fix the cells.  After 
emptying the wells of methanol, the glioblastoma cancer cells were treated with crystal violet 
stain for an additional 5 minutes to effectively stain the cells for easier visualization.  The 
purpose of staining the glioblastoma cancer cells with crystal violet was to facilitate the cell 
viability count, allowing easy identification of the remaining cancer cells and to determine the 
percent of the cell population that died after administering the compound.  After the 5-minute 
setting period, the crystal violet stain was removed, and each well was washed with DI water to 
remove any residual stain.  These plates were allowed to dry over the next couple of days.   
To determine the LC50 of each compound, I counted my cell assays with a digital 
microscope.  9 points were designated on cell well to standardize counting among all wells; each 
point had a 25 mm2 field of view.  Within these points, the number of visible cells were counted, 
and the number of cell counts for a specific dilution from all three cell viability plates were 
averaged.  From these values, the standard deviation and standard error mean was calculated.  T-
tests (with a of 0.05) were also conducted on each value to determine its statistical significance.  










































In terms of the chemical aspect of this study, pancreatin can be used as a biocatalyst in 
the syntheses of novel heterocyclic arylidenes containing rhodanine-3-acetic acid and select set 
of benzaldehydes.  However, NMR analyses revealed that residual aldehydes still remained in 











2-chlorobenzaldehyde 86.6% Present 
R3-3CBA Rhodanine-3-acetic 
acid 
3-chlorobenzaldhyde 66.0% Present 
R3-4CBA Rhodanine-3-acetic 
acid 
4-chlorobenzaldehyde 85.1% Absent 
R3-2FBA Rhodanine-3-acetic 
acid 
2-fluorobenzaldehyde 70.9% Absent 
R3-3FBA Rhodanine-3-acetic 
acid 
3-fluorobenzaldehyde 55.9% Present 
R3-4FBA Rhodanine-3-acetic 
acid 
4-fluorobenzaldehyde 80.5% Present 
R3-2BBA Rhodanine-3-acetic 
acid 
2-bromobenzaldehyde 73.2% Absent 
R3-3BBA Rhodanine-3-acetic 
acid 
3-bromobenzaldehyde 96.4% Present 
R3-4BBA Rhodanine-3-acetic 
acid 
















Tab. 1 List of hybrid derivatives along with starting reagents, percent, yield, and analysis of IR and NMR for 
presence of residual aldehydes 
 
Percent yields varied depending on the type of substituent group on the compound’s 
benzene ring as shown on this data table.  Percent yields for brominated arylidenes had the 
highest yield ranging from 73.2% to 96.4%.  Chlorinated arylidenes ranged from 66.0% to 
86.6%, whereas fluorinated arylidenes ranged from 55.9% to 80.5%.  Heterocyclic arylidenes 
containing a boronic acid substituent produced relatively poorer yields compared to their 
halogenated counterparts, ranging from 4.70% to 34.9%.  
Percent yields also varied depending on the substituent group’s position on the 
arylidene’s benzene ring.  Percent yields were higher for arylidenes containing a chlorine, 
fluorine, and boronic acid substituent group on the 2nd or 4th position compared to the 3rd 
position; brominated compounds were an exception to this trend with the 3rd position actually 


































The purpose of investigating these novel compounds and administering different dilutions 
in each well is to determine the compound’s LC50.  As mentioned before, the LC50 is the lethal 
dose at which 50% of the sample population dies.  A smaller dose that causes 50% lethality is 
ideal because it requires less of the compound in order to elicit its lethal effects on glioblastoma 
cancer cells. In other words, the smaller the dose, the more potent the drug. 
Although there was some decrease in U87 glioblastoma cell viability with the 
administration of these heterocyclic arylidenes, their generally high LC50 and their t-tests 
indicate that this decrease is not statistically significant.  Despite this, there was some variance in 
anticancer activity among heterocyclic arylidenes containing different substituent groups.  
Fluorinated and brominated arylidenes exhibited the lowest LC50 compared to other compounds, 
ranging between 0.063 mg/ml to 0.25 mg/ml.  Chlorinated compounds’ LC50 revolved around 
0.25 mg/ml.  Arylidenes containing a boronic acid substituent group exhibited the highest LC50 
ranging from 0.25 mg/ml to 1 mg/ml.   
Comparing the LC50 of heterocyclic arylidenes with the same substituent functional 
group but different substituent position, substituent placement had no significant effect on the 
novel compound’s anticancer activity.  Although there was a differential in LC50 values among 
compounds with different placement, these differences were minimal.   
When comparing these heterocyclic arylidenes to their starting materials, some starting 
reagents, especially benzaldehydes containing a boronic acid substituent, actually had a lower 
LC50 compared to that of their respective heterocyclic arylidene.  This is shown in the bar graphs 
between these boronated benzaldehydes and their respective heterocyclic counterparts.  This 
comparison between the starting reagents and hybrid drugs’ LC50 suggests that the addition of a 






Fig. 27-32 Cell viability count per 25 mm2 per well at progressively lower concentrations of various starting 
reagents.  Some starting reagents were not tested because they were insoluble in DMSO.  Arrow indicates LC50, and 








Fig. 33-44 Cell viability count per 25 mm2 per well at progressively lower concentrations of all 12 heterocyclic 
arylidenes.  Higher concentrations for some products were excluded because solid precipitates obscured 

















Although this line of research has not necessarily yielded any promising results, there 
have been significant developments in enhancing our knowledge of novel hybrid derivatives and 
improving our experimental protocol.  Unlike previous undergraduate and graduate studies 
conducted years before, this research is the first to study the effects of brominated heterocyclic 
arylidenes as well as compounds containing rhodanine-3-acetic acid in Dr. Smith’s lab.   
Along with researching the biological activity of this new class of heterocyclic 
arylidenes, this study has also explored enzymes as potential biocatalysts in condensation 
reactions.  Previous undergraduate and graduate researchers have relied on calcium oxide as a 
catalyst in their organic syntheses.  However, this inorganic catalyst can be difficult to remove 
during purification and has a deleterious effect on cancer cell viability; this inadvertently skews 
cell counts, resulting in inaccurate data.  This method employed an alternative biocatalyst that 
does not have any known adverse effects on cell survival and be easily denatured or deactivated 
with high salt solutions and extremely high temperatures.   
In terms of improving experimental protocol, this study is also one of the first this year to 
use a digital microscope to count fixed glioblastoma cells.  Use of this digital microscope has 
enhanced the accuracy of my results as compared to the original method of individually counting 
cells with a phase contrast light microscope.  Unlike the new digital method, the other method 
was prone to inaccurate counts, leading to enlarged errors bars on the graphs.  Additionally, my 
study is one of the first to make a cross comparative analysis between the starting reagents and 
their corresponding heterocyclic arylidenes to observe any differences in biological behavior and 
anticancer activity. 
Despite the developments that were made in my research, there are still some weaknesses 
that need to be addressed.  Although the biocatalyst, pancreatin, shows some promise as an 
alternative catalyst, NMR analyses reveal that 50% of the final product are impure.  Although the 
presence of residual aldehyde peaks in the NMR are very small, this still places doubt on 
pancreatin’s reliability as a biocatalyst.   
In terms of the compounds investigated during this study, some starting reagents, more 
specifically 2-chlorobenzaldehyde, 3- chlorobenzaldehyde, 4- fluorobenzaldehyde, 2- 
bromobenzaldehyde, and 3- bromobenzaldehyde did not completely dissolve in DMSO while 
making primary stock solutions.  As a result, some compounds were unable to administer them 
in a 12-well cell plate, and a comparison between these starting materials and their 
corresponding arylidene products.  Additionally, 2-fluorobenzaldehyde and 3-
fluorobenzaldehyde were not tested because there was not enough in stock to conduct an assay.  
Some heterocyclic arylidenes, namely R3-3CBA, R3-4CBA, R3-3BBA, R3-4BBA, precipitated 
out of solution when added with media at a high concentration, resulting in solids obscuring any 
possible visualization of that particular well.  
Although improvements to the experimental protocol have been made, there are still 
some issues.  In terms of the counting method, it is difficult to distinguish cells.  Although the 
resolution is significantly enhanced, neurospheres, large clumps of cancer cells, make it difficult 
to accurately count each cell individually.  As a result, the number of cells were approximated 
within each neurosphere, counting only cells that I can visibly distinguish.  Another possible 
source of error was inappropriate technique or use of equipment.  For example, washing away 
any residual crystal violet stain too vigorously or mishandling of micropipettes during plate set-
up, may inadvertently reduce the number of cells that should be there.  However, a major 
weakness in this study is the fungal contamination that had plagued the lab’s incubator.  
Unfortunately, due to improper handling or neglect, fungal spores have infiltrated many of the 
cell culture plates, completely decimating entire cell populations and compromising many cell 
assay plates.  Because of their invasive and deleterious nature, these fungal spores pose an 
immense threat to the integrity of this study since the entire premise of this research is to assess 
cancer cell viability when exposed to graded concentration of a potential anticancer drug.   
For future studies, these class of heterocyclic arylidenes and their reagents could be tested 
on other cancer types and lines to observe their biological activity in response to the drug.  These 
studies would involve revising the synthesis or purification method of the experimental protocol 
to completely remove any residual aldehydes in the final product.  However, a more promising 
inquiry that is investigating another class of heterocyclic arylidenes synthesized by Jemma 
McLeish.  McLeish previously synthesized a set of chlorinated heterocyclic arylidenes that were 
structurally similar my own; however, instead of using rhodanine-3-acetic acid, she synthesized 
these compounds with simple rhodanine, which lacks an acetic acid group.  In this comparative 
study, a set of chlorinated heterocyclic arylidenes will be recreated and tested on U87 
glioblastoma cells to observe any similarities or differences that the absence of an acetyl group 
































In conclusion, a class of heterocyclic arylidenes were synthesized from rhodanine-3-
acetic acid and a select set of benzaldehydes via a 3-hour, pancreatin-catalyzed controlled reflux 
reaction with limited success, as 50% of these products still contain residual benzaldehydes.  In 
terms of their biological activity, their high LC50 indicate that this class of heterocyclic 
arylidenes are not strong candidates as anticancer agents against GBM.  Furthermore, the 
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